Brought to you by 
JJDC buys $33mm in Bavarian Nordic equity
22 Aug 2017
Executive Summary
Johnson & Johnson's Johnson & Johnson Development Corp. purchased $32.8mm (DKK207.5mm) new Bavarian Nordic AS stock in a private placement of 512,102 shares priced at $64.18. As a result, JJDC now holds 1,844,086 shares in Bavarian Nordic corresponding to 5.77% of the share capital and voting rights. The financing is part of a concurrent deal between Bavarian Nordic and J&J's Janssen Pharmaceuticals Inc. subsidiary in which Janssen received exclusive global rights to use MVA-BN technology to develop vaccines for hepatitis B virus and HIV.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
JJDC buys $33mm in Bavarian Nordic equity
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice